Skip to main content
SpringerLink
Log in

Clinical utility of 68Ga-DOTATOC positron emission tomography/computed tomography for recurrent renal cell carcinoma

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Positron emission tomography (PET)/computed tomography (CT) with 68Ga-labelled 1,4,7,10-tetraazacyclododecane-N,N′,N″,N″‘-tetraacetic acid-d-Phe1-Tyr3-octreotide (DOTATOC) has been accepted as a diagnostic imaging tool especially for patients with neuroendocrine tumours. However, its clinical usefulness for restaging of renal cell carcinoma (RCC) has not been fully investigated. This retrospective study was performed to elucidate the clinical value of PET/CT using 68Ga-DOTATOC in patients with known or suspected recurrent RCC.

Methods

We analysed 25 consecutive patients who underwent DOTATOC-PET/CT scans after surgery for RCC (23 clear cell, 1 papillary, 1 unclassified). PET/CT findings were reviewed and the detection rate was calculated on a patient and lesion basis. The detectability was compared in patients who also underwent PET/CT scans with 18F-fluorodeoxyglucose (FDG). Histopathological findings or clinical follow-up were used as the reference standard.

Results

Based on the final diagnosis, 76 recurrent or metastatic lesions were confirmed in this population. Of these lesions, 66 lesions in 22 patients were positive by DOTATOC-PET/CT. The patient-based and lesion-based sensitivity was 88% (22/25) and 87% (66/76), respectively. Twelve patients underwent both DOTATOC-PET/CT and FDG-PET/CT. The lesion-based sensitivity of DOTATOC was 74% (20/27), while that of FDG was 59% (16/27). Eight lesions were identified only by DOTATOC, but four lesions from papillary RCC were detected only by FDG.

Conclusion

Our data indicate that DOTATOC-PET/CT would be useful for detecting recurrent foci in patients with clear cell RCC. DOTATOC-PET/CT and FDG-PET/CT are considered to have complementary roles.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373:1119–32.

    Article  CAS  PubMed  Google Scholar 

  2. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67:913–24.

    Article  PubMed  Google Scholar 

  3. Bedke J, Gauler T, Grünwald V, Hegele A, Herrmann E, Hinz S, et al. Systemic therapy in metastatic renal cell carcinoma. World J Urol. 2017;35:179–88.

    Article  CAS  PubMed  Google Scholar 

  4. Volpe A, Bollito E, Bozzola C, Di Domenico A, Bertolo R, Zegna L, et al. Classification of histologic patterns of pseudocapsular invasion in organ-confined renal cell carcinoma. Clin Genitourin Cancer. 2016;14:69–75.

    Article  PubMed  Google Scholar 

  5. Ma H, Shen G, Liu B, Yang Y, Ren P, Kuang A. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis. Nucl Med Commun. 2017;38:156–63.

    Article  PubMed  Google Scholar 

  6. Reubi JC, Kvols L. Somatostatin receptors in human renal cell carcinomas. Cancer Res. 1992;52:6074–8.

    CAS  PubMed  Google Scholar 

  7. Vikić-Topić S, Raisch KP, Kvols LK, Vuk-Pavlović S. Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin Endocrinol Metab. 1995;80:2974–9.

    PubMed  Google Scholar 

  8. Kassabian A, Stein J, Jabbour N, Parsa K, Skinner D, Parekh D, et al. Renal cell carcinoma metastatic to the pancreas: a single-institution series and review of the literature. Urology. 2000;56:211–5.

    Article  CAS  PubMed  Google Scholar 

  9. Chan K, Luong TV, Navalkissoor S. 111In-DTPA-octreotide SPECT (OctreoScan) uptake in metastatic renal cell carcinoma to the pancreas. Clin Nucl Med. 2018;43:e29–30.

    Article  PubMed  Google Scholar 

  10. Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L, et al. The impact of somatostatin receptor-directed PET/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis. J Nucl Med. 2017;58:756–61.

    Article  PubMed  Google Scholar 

  11. Graham MM, Gu X, Ginader T, Breheny P, Sunderland JJ. (68)Ga-DOTATOC imaging of neuroendocrine tumors: a systematic review and metaanalysis. J Nucl Med. 2017;58:1452–8.

    Article  CAS  PubMed  Google Scholar 

  12. Deppen SA, Blume J, Bobbey AJ, Shah C, Graham MM, Lee P, et al. 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. J Nucl Med. 2016;57:872–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Peter L, Sänger J, Hommann M, Baum RP, Kaemmerer D. Molecular imaging of late somatostatin receptor-positive metastases of renal cell carcinoma in the pancreas by 68Ga DOTATOC PET/CT: a rare differential diagnosis to multiple primary pancreatic neuroendocrine tumors. Clin Nucl Med. 2014;39:713–6.

    Article  PubMed  Google Scholar 

  14. Vamadevan S, Le K, Shen L, Loh H, Mansberg R. 68Ga-DOTATATE uptake in solitary pancreatic metastasis from clear cell renal Cancer. Clin Nucl Med. 2017;42:700–1.

    Article  PubMed  Google Scholar 

  15. Nadebaum DP, Lee ST, Nikfarjam M, Scott AM. Metastatic clear cell renal cell carcinoma demonstrating intense uptake on (68)Ga-DOTATATE positron emission tomography: three case reports and a review of the literature. World J Nucl Med. 2018;17:195–7.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Vamadevan S, Le K, Shen L, Stevanovic A, Loh H, Mansberg R. 68Ga-DOTATATE uptake in a soft tissue metastasis from clear cell renal cell cancer. Clin Nucl Med. 2018;43:44–5.

    Article  CAS  PubMed  Google Scholar 

  17. Nakatani K, Nakamoto Y, Saga T, Higashi T, Togashi K. The potential clinical value of FDG-PET for recurrent renal cell carcinoma. Eur J Radiol. 2011;79:29–35.

    Article  PubMed  Google Scholar 

  18. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22:4991–5004.

    Article  CAS  PubMed  Google Scholar 

  19. Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. Ann Nucl Med. 2015;29:877–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS. Utility of (68) Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat Oncol. 2017;61:372–8.

    Article  PubMed  Google Scholar 

  21. Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42:1284–94.

    Article  PubMed  Google Scholar 

  22. Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:926–37.

    Article  PubMed  Google Scholar 

  23. Yin Y, Campbell SP, Markowski MC, Pierorazio PM, Pomper MG, Allaf ME, et al. Inconsistent detection of sites of metastatic non-clear cell renal cell carcinoma with PSMA-targeted [(18)F]DCFPyL PET/CT. Mol Imaging Biol. 2018. https://doi.org/10.1007/s11307-018-1271-2.

Download references

Funding

This study was funded by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (25461816).

Author information

Authors and Affiliations

  1. Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan

    Yuji Nakamoto, Takayoshi Ishimori & Kaori Togashi

  2. Laboratory of Biophysical Chemistry, Kobe Pharmaceutical University, Kobe, Japan

    Yoichi Shimizu & Kohei Sano

Authors
  1. Yuji Nakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takayoshi Ishimori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoichi Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kohei Sano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kaori Togashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuji Nakamoto.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the ethics committee of Kyoto University Graduate School and Faculty of Medicine Kyoto University Hospital (reference number C0454).

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakamoto, Y., Ishimori, T., Shimizu, Y. et al. Clinical utility of 68Ga-DOTATOC positron emission tomography/computed tomography for recurrent renal cell carcinoma. Eur J Nucl Med Mol Imaging 46, 1524–1530 (2019). https://doi.org/10.1007/s00259-019-04298-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-019-04298-4

Keywords

Search

Navigation